A Phase 4 interventional study of Insulin Glulisine and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-06.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 4, and was the 11th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 588 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 281 across the 25 interventional studies. Of the 24 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 26 have an industry lead sponsor. The 7 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 35th largest by enrollment of the 178 interventional ones that give a count, is one of 10 that started in 2006, is one of 75 in phase 4, and was the 32nd registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives were:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
Drug: Insulin Glargine · Drug: Insulin Glulisine
Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
Drug: Insulin Glulisine · Drug: Insulin Glargine
Premixed insulin (Novolog® Mix 70/30) added to oral agents.
Drug: Premixed Insulin
Subcutaneous injection up to 1 injection per day
Also known as: Apidra
Subcutaneous injection once-a-day
Also known as: Lantus
Subcutaneous injection twice-a-day.
Also known as: Novolog Mix 70/30
Subcutaneous injection up to 3 injections per day.
Also known as: Apidra
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)
Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.
Time frame: At week 60
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population
Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.
Time frame: At week 60
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)
Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.
Time frame: At week 60
Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)
Absolute Change in HbA1c from Baseline to Week 60.
Time frame: From baseline to week 60
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)
Patients who achieved an HbA1c value \<7.0% were defined as responders. Patients who did not achieve HbA1c values \<7.0% and patients with missing HbA1c values were considered nonresponders.
Time frame: At week 60
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl
Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration. A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of \<50 mg/dL with reported symptoms.
Time frame: At week 60
Adjusted Incidence Rate of Hypoglycemia
Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia. A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) \<36 mg/dL during or soon after the event. A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion. Nocturnal = events occurring between 00:00 \& 06:00 based on a 24-hour clock. An event is included if the HE start date is within the treatment period.
Time frame: Week 60
Adjusted Hypoglycemic Event Rates (Event/Patient-year)
Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study. An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to \& including 1 day after the date of last dose of study drug).
Time frame: Week 60
A total of 123 study sites were activated in the United States; 99 sites enrolled and randomized 588 patients from May 2006 to March 2010. 582 patients out of 588 patients were treated. Three sites (which included 26 patients) were found to be non Good Clinical Practices (GCP) compliant.
| Milestone | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| Started | 195 | 196 | 197 |
| Intent-to-treat (itt) | 195 | 196 | 197 |
| Treated (safety population) | 194 | 194 | 194 |
| Intent-to-treat (excluding nongcp sites) | 187 | 186 | 189 |
| Completed | 156 | 150 | 141 |
| Not completed | 39 | 46 | 56 |
| Withdrew: Adverse event | 5 | 5 | 4 |
| Withdrew: Lack of efficacy | 0 | 3 | 2 |
| Withdrew: No longer requires study treatment | 1 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 9 | 9 | 10 |
| Withdrew: Progressive disease | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 14 | 19 | 29 |
| Withdrew: Patient non-compliant | 4 | 4 | 5 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Loss of site personnel | 1 | 0 | 1 |
| Withdrew: Sponsor decision | 1 | 2 | 1 |
| Withdrew: Patient moved | 1 | 0 | 1 |
| Withdrew: Patient required surgery | 0 | 1 | 0 |
Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.
| percentage of participants | Lantus/Apidra-3 | Novolog Mix 70/30 |
|---|---|---|
| HbA1c < 7.0% | 43.3 | 38.6 |
| HbA1c ≥ 7.0% | 35.3 | 32.3 |
| Missing data | 21.4 | 29.1 |
Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.
| percent HbA1c | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|
| baseline HbA1c | 9.30 ± 0.176 | 9.06 ± 0.187 |
| Absolute change in HbA1c from baseline | -2.30 ± 0.126 | -1.97 ± 0.132 |
Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.
| percentage of participants | Lantus/Apidra-3 | Novolog Mix 70/30 |
|---|---|---|
| HbA1c < 7.0% | 44.1 | 38.1 |
| HbA1c ≥ 7.0% | 34.4 | 32.0 |
| Missing data | 21.5 | 29.9 |
Absolute Change in HbA1c from Baseline to Week 60.
| percent HbA1c | Lantus/Apidra-3 | Novolog Mix 70/30 |
|---|---|---|
| Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30) | -2.45 ± 0.134 | -2.13 ± 0.142 |
Patients who achieved an HbA1c value \<7.0% were defined as responders. Patients who did not achieve HbA1c values \<7.0% and patients with missing HbA1c values were considered nonresponders.
| percentage of participants | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|
| Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30) | 51.1 | 39.5 |
Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration. A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of \<50 mg/dL with reported symptoms.
| percentage of participants | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| HbA1c < 7.0% | 23.0 | 25.0 | 14.1 |
| HbA1c ≥ 7.0% | 55.7 | 52.2 | 58.4 |
| Missing data | 21.3 | 22.8 | 27.6 |
Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia. A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) \<36 mg/dL during or soon after the event. A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion. Nocturnal = events occurring between 00:00 \& 06:00 based on a 24-hour clock. An event is included if the HE start date is within the treatment period.
| estimated percentage per patient | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| Self-Monitored Blood Glucose (SMBG) < 70 mg/dl | 74.40 ± 3.83 | 74.78 ± 3.80 | 83.15 ± 3.11 |
| SMBG< 70 mg/dl with symptoms | 60.14 ± 4.24 | 62.50 ± 4.18 | 71.98 ± 3.76 |
| SMBG< 70 mg/dl, nocturnal | 46.30 ± 4.28 | 40.31 ± 4.18 | 42.53 ± 4.19 |
| SMBG< 70 mg/dl with symptoms, nocturnal | 37.03 ± 4.10 | 33.55 ± 3.98 | 35.68 ± 4.03 |
| SMBG< 50 mg/dl | 39.77 ± 4.27 | 39.55 ± 4.25 | 53.14 ± 4.33 |
| SMBG< 50 mg/dl with symptoms | 31.51 ± 3.95 | 32.56 ± 4.00 | 45.92 ± 4.30 |
| SMBG< 50 mg/dl, nocturnal | 12.05 ± 2.88 | 11.29 ± 2.78 | 12.58 ± 2.96 |
| SMBG< 50 mg/dl with symptoms, nocturnal | 6.93 ± 2.28 | 7.49 ± 2.43 | 8.88 ± 2.76 |
| SMBG< 36 mg/dl | 10.89 ± 2.23 | 8.63 ± 2.02 | 14.32 ± 2.52 |
| Severe hypoglycemias | 10.10 ± 2.17 | 7.19 ± 1.85 | 8.23 ± 1.97 |
| Serious hypoglycemias | 0.41 ± 0.43 | 0.00 ± 0.00 | 2.29 ± 1.12 |
Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study. An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to \& including 1 day after the date of last dose of study drug).
| event per patient year | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| Self-Monitored Blood Glucose (SMBG) < 70 mg/dl | 14.50 ± 1.72 | 12.85 ± 1.50 | 20.42 ± 2.38 |
| SMBG< 70 mg/dl with symptoms | 7.23 ± 0.99 | 7.11 ± 0.99 | 12.23 ± 1.68 |
| SMBG< 70 mg/dl, nocturnal | 1.90 ± 0.32 | 1.84 ± 0.31 | 1.68 ± 0.29 |
| SMBG< 70 mg/dl with symptoms, nocturnal | 1.16 ± 0.21 | 1.10 ± 0.21 | 1.16 ± 0.23 |
| SMBG< 50 mg/dl | 1.38 ± 0.21 | 1.17 ± 0.19 | 2.42 ± 0.36 |
| SMBG< 50 mg/dl with symptoms | 0.89 ± 0.15 | 0.83 ± 0.15 | 1.91 ± 0.31 |
| SMBG< 50 mg/dl, nocturnal | 0.20 ± 0.06 | 0.18 ± 0.06 | 0.27 ± 0.09 |
| SMBG< 50 mg/dl with symptoms, nocturnal | 0.10 ± 0.04 | 0.09 ± 0.04 | 0.18 ± 0.07 |
| SMBG< 36 mg/dl | 0.15 ± 0.03 | 0.10 ± 0.03 | 0.23 ± 0.05 |
| Severe hypoglycemias | 0.17 ± 0.05 | 0.10 ± 0.03 | 0.17 ± 0.05 |
| Serious hypoglycemias | NA ± NA | NA ± NA | NA ± NA |
Collected over All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lantus/Apidra-3 | — | 22/194 (11.3%) | 140/194 (72.2%) |
| Lantus/Apidra-1 | — | 23/194 (11.9%) | 150/194 (77.3%) |
| Novolog Mix 70/30 | — | 21/194 (10.8%) | 152/194 (78.4%) |
| Event | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| Angina pectorisCardiac disorders | 1/194 | 3/194 | 2/194 |
| Hypoglycaemic unconsciousnessMetabolism and nutrition disorders | 1/194 | 0/194 | 3/194 |
| Acute myocardial infarctionCardiac disorders | 2/194 | 1/194 | 0/194 |
| Angina unstableCardiac disorders | 1/194 | 2/194 | 0/194 |
| Urinary tract infectionInfections and infestations | 0/194 | 2/194 | 0/194 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/194 | 1/194 | 1/194 |
| Renal failure acuteRenal and urinary disorders | 2/194 | 0/194 | 0/194 |
| Acute coronary syndromeCardiac disorders | 0/194 | 1/194 | 0/194 |
| Atrial fibrillationCardiac disorders | 1/194 | 0/194 | 0/194 |
| Coronary artery occlusionCardiac disorders | 1/194 | 1/194 | 0/194 |
| Event | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 |
|---|---|---|---|
| Any infections and infestationsInfections and infestations | 66/194 | 82/194 | 90/194 |
| Any musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 45/194 | 44/194 | 40/194 |
| Any nervous system disordersNervous system disorders | 39/194 | 29/194 | 27/194 |
| Any gastrointestinal disordersGastrointestinal disorders | 33/194 | 32/194 | 30/194 |
| Any general disorders and administration site conditionsGeneral disorders | 21/194 | 28/194 | 25/194 |
| Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 19/194 | 27/194 | 23/194 |
| Upper respiratory tract infectionInfections and infestations | 18/194 | 20/194 | 25/194 |
| SinusitisInfections and infestations | 6/194 | 19/194 | 16/194 |
| NasopharyngitisInfections and infestations | 15/194 | 17/194 | 8/194 |
| Oedema peripheralGeneral disorders | 14/194 | 11/194 | 10/194 |
| Age Continuous(years) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 10.54 | 53.7 ± 9.11 | 53.7 ± 10.65 | 54.1 ± 10.12 |
| Sex: Female, Male(Participants) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Female | 78 | 88 | 86 | 252 |
| Male | 117 | 108 | 111 | 336 |
| Region of Enrollment(participants) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| United States | 195 | 196 | 197 | 588 |
| Weight(kilograms (kg)) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Mean | 95.2 ± 19.21 | 97.2 ± 20.88 | 97.9 ± 20.49 | 96.8 ± 20.21 |
| Body Mass Index (BMI)(Kilogram/m^2) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Mean | 32.7 ± 5.79 | 33.4 ± 6.00 | 33.4 ± 5.62 | 33.1 ± 5.80 |
| Duration of diabetes at study entry(years) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Mean | 9.4 ± 6.80 | 9.1 ± 5.70 | 9.5 ± 5.87 | 9.3 ± 6.13 |
| Age at onset of diabetes(years) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| Mean | 46.0 ± 10.74 | 45.1 ± 9.36 | 44.8 ± 10.01 | 45.3 ± 10.05 |
| Oral antidiabetic treatment combination at study entry(participants) | Lantus/Apidra-3 | Lantus/Apidra-1 | Novolog Mix 70/30 | Total |
|---|---|---|---|---|
| sulfonylurea (SU) or meglitinide plus metformin | 97 | 99 | 97 | 293 |
| SU or meglitinide plus thiazolinedione (TZD) | 9 | 9 | 10 | 28 |
| TZD plus metformin | 26 | 27 | 27 | 80 |
| SU or meglitinide plus metformin plus TZD | 63 | 61 | 63 | 187 |
The record gives a start of May 2006, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin glulisine · Insulin Glargine